By Elaine Rigoli
Tampa, Fla., May 8 -Protagen AG has closed its second round of financing, this time with MIG AG Funds 1 and 3 and Dortmund GmbH, for €3.3 million.
Protagen said it has successfully switched from a fee-for-service company to a product company. By introducing the protein biochip products UNIchip AV-400 and UNIchip AV-VAR customers, the entire biotech and pharmaceutical industry can profit from safer and more efficient development of monoclonal antibodies, the company said in a news release.
The money from the actual financing round will be used to expand the sales activities in Europe and the United States and to broaden the product pipeline, the release said.
Based in Dortmund, Germany, Protagen develops technologies in proteomics, protein biochips and bioinformatics into services and products for the life science industries and academia.
| Issuer: | Protagen AG
|
| Issue: | Venture capital
|
| Amount: | €3.3 million
|
| Investors: | MIG AG Funds 1 and 3, Dortmund GmbH
|
| Announcement date: | May 8
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
